MBOT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Microbot Medical Inc. (MBOT) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has promising technology and analyst ratings are positive, the financial performance is weak, and there are no strong trading signals or significant catalysts to justify immediate investment. A hold is recommended until further positive developments or stronger signals emerge.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 69.298, and moving averages are converging, showing no clear trend. The pre-market price is $2.15, up 2.87%, with resistance levels at $2.147 and $2.3, and support levels at $1.899 and $1.651.
The Liberty Endovascular Robotic System is the only FDA-cleared system for peripheral vascular procedures, with expected commercial traction due to its unique disposable model. Analysts have initiated buy ratings with price targets of $5 and $5.50, citing strong potential for adoption.
EPS dropped significantly by 65% YoY. Additionally, there are no recent insider or hedge fund buying trends, and no congress trading data.
In Q3 2025, revenue was $0 with no YoY growth. Net income improved slightly by 11.26% YoY but remains negative at -$3.58 million. EPS dropped by 65% YoY to -$0.07, indicating weak financial health.
Two analysts have initiated buy ratings with price targets of $5 and $5.50, citing the unique advantages of the Liberty Endovascular Robotic System and its potential for rapid adoption in the market.
